Invitae Corporation (NVTA)
Invitae Corporation operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in San Francisco, CA, US. The stock last traded at $0.02, down 35.59% on the session, giving a market capitalisation of $5.4M. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -601.6%. Its beta of 1.59 implies it has historically moved more than the broad market.
Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators. Established in 2010 as Locus Development, Inc., the company officially became Invitae Corporation in 2012 and is headquartered in San Francisco, California.
Invitae Corporation is most often compared with the following Healthcare names: